These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16133798)

  • 1. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
    Advani R; Lum BL; Fisher GA; Halsey J; Geary RS; Holmlund JT; Kwoh TJ; Dorr FA; Sikic BI
    Invest New Drugs; 2005 Oct; 23(5):467-77. PubMed ID: 16133798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer.
    Nemunaitis J; Holmlund JT; Kraynak M; Richards D; Bruce J; Ognoskie N; Kwoh TJ; Geary R; Dorr A; Von Hoff D; Eckhardt SG
    J Clin Oncol; 1999 Nov; 17(11):3586-95. PubMed ID: 10550158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
    Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
    Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
    Grossman SA; Alavi JB; Supko JG; Carson KA; Priet R; Dorr FA; Grundy JS; Holmlund JT
    Neuro Oncol; 2005 Jan; 7(1):32-40. PubMed ID: 15701280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
    Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
    Advani R; Peethambaram P; Lum BL; Fisher GA; Hartmann L; Long HJ; Halsey J; Holmlund JT; Dorr A; Sikic BI
    Cancer; 2004 Jan; 100(2):321-6. PubMed ID: 14716767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
    Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
    Sausville EA; Arbuck SG; Messmann R; Headlee D; Bauer KS; Lush RM; Murgo A; Figg WD; Lahusen T; Jaken S; Jing X; Roberge M; Fuse E; Kuwabara T; Senderowicz AM
    J Clin Oncol; 2001 Apr; 19(8):2319-33. PubMed ID: 11304786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.
    Cunningham CC; Holmlund JT; Geary RS; Kwoh TJ; Dorr A; Johnston JF; Monia B; Nemunaitis J
    Cancer; 2001 Sep; 92(5):1265-71. PubMed ID: 11571742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
    Adjei AA; Dy GK; Erlichman C; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton PJ; Watanabe T; Geary RS; Holmlund J; Dorr FA
    Clin Cancer Res; 2003 Jan; 9(1):115-23. PubMed ID: 12538459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
    Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
    Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
    Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
    Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A).
    Stevenson JP; Yao KS; Gallagher M; Friedland D; Mitchell EP; Cassella A; Monia B; Kwoh TJ; Yu R; Holmlund J; Dorr FA; O'Dwyer PJ
    J Clin Oncol; 1999 Jul; 17(7):2227-36. PubMed ID: 10561280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors.
    Goel S; Desai K; Bulgaru A; Fields A; Goldberg G; Agrawal S; Martin R; Grindel M; Mani S
    Clin Cancer Res; 2003 Sep; 9(11):4069-76. PubMed ID: 14519628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
    Yuen AR; Halsey J; Fisher GA; Holmlund JT; Geary RS; Kwoh TJ; Dorr A; Sikic BI
    Clin Cancer Res; 1999 Nov; 5(11):3357-63. PubMed ID: 10589745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
    Tan AR; Headlee D; Messmann R; Sausville EA; Arbuck SG; Murgo AJ; Melillo G; Zhai S; Figg WD; Swain SM; Senderowicz AM
    J Clin Oncol; 2002 Oct; 20(19):4074-82. PubMed ID: 12351605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.